MedTrace Logo

The Practical Evidence of Antidiabetic Combination Therapy in Korea

NCT02231021 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 216

Last updated 2019-02-08

No results posted yet for this study

Summary

This study evaluate the efficacy and safety of alogliptin and pioglitazone combination therapy in comparison with either alogliptin or pioglitazone on glucose control in the metformin-treated type 2 diabetic patients in Korea.

Conditions

Interventions

DRUG

alogliptin

alogliptin 25 mg add-on background medication metformin

DRUG

Pioglitazone

pioglitazone 30 mg add-on background medication metformin

DRUG

alogliptin + pioglitazone

alogliptin 25 mg and pioglitazone 30 mg add-on background medication metformin

Sponsors & Collaborators

  • Takeda

    collaborator INDUSTRY

  • Kun-Ho Yoon

    lead OTHER

Principal Investigators

  • Kun-Ho Yoon, MD, PhD · Seoul St Mary's Hospital, The Catholic Univerisity of Korea

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2018-10-22
Completion
2019-01-28

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02231021 on ClinicalTrials.gov